Comparative Pharmacology
Head-to-head clinical analysis: PENAPAR VK versus PENICILLIN G SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENAPAR VK versus PENICILLIN G SODIUM.
PENAPAR-VK vs PENICILLIN G SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours; maximum 2 g/day.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic